St. Jude Children's Research Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1962-01-01

Employees: -

Market Cap: -

Website: http://www.stjude.org/

Clinical Trials

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

Not Applicable

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Transcranial Direct Current Stimulation
Executive Dysfunction

Interventions: Device: Cathodal tDCS treatment
Device: Sham treatment
Device: Anodal tDCS treatment
Other: NIH Toolbox List Sorting Working Memory Test
Other: NIH Toolbox Flanker Inhibitory Control and Attention Test
Other: Grooved Peg Board Test
Other: Buschke Selective Reminding Test

First Posted Date: 2019-09-26

Last Posted Date: 2024-01-12

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 36

Registration Number: NCT04105530

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Indocyanine Green (ICG) Guided Tumor Resection

Phase 1

Recruiting

Conditions: Neoplastic Disease
Solid Tumor

Interventions: Drug: Indocyanine Green

First Posted Date: 2019-09-10

Last Posted Date: 2024-08-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 312

Registration Number: NCT04084067

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization

Not Applicable

Completed

Conditions: Sickle Cell Disease

Interventions: Behavioral: HU Toolbox mobile application
Behavioral: InCharge Health mobile application

First Posted Date: 2019-09-06

Last Posted Date: 2023-11-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 382

Registration Number: NCT04080167

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Georgia Regents University, Augusta, Georgia, United States

and more 4 locations

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

Not Applicable

Recruiting

Conditions: Pilocytic Astrocytoma
Diffuse Astrocytoma
Pleomorphic Xanthoastrocytoma
Ganglioglioma
Optic Pathway Glioma
Pilomyxoid Astrocytoma
Glioma

Interventions: Radiation: Hippocampal-avoidance proton therapy

First Posted Date: 2019-08-22

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 74

Registration Number: NCT04065776

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Patient-Reported Outcome Version of the Common Criteria for Adverse Events

Recruiting

Conditions: Survivorship
Cancer

Interventions: Other: Community non-cancer control
Other: SJLIFE
Other: Childhood Cancer Survivors (CCSS)

First Posted Date: 2019-08-08

Last Posted Date: 2024-08-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 765

Registration Number: NCT04050072

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Phase 1

Active, not recruiting

Conditions: Brain Tumor, Refractory
Brain Cancer
CNS Cancer
Brain Tumor
CNS Tumor
Medulloblastoma, Non-WNT/Non-SHH
CNS Neoplasm
Brain Tumor, Recurrent
Medulloblastoma
Medulloblastoma Recurrent

Interventions: Drug: Prexasertib
Drug: Cyclophosphamide
Drug: Gemcitabine
Biological: filgrastim
Biological: peg-filgrastim

First Posted Date: 2019-07-17

Last Posted Date: 2024-03-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 21

Registration Number: NCT04023669

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

Not Applicable

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Device: Active tDCS
Device: Sham tDCS

First Posted Date: 2019-07-05

Last Posted Date: 2023-07-27

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 127

Registration Number: NCT04007601

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

T-cell Responses to Concurrent HIV and Herpesvirus Infections

Completed

Conditions: HIV
HIV Infections

Interventions: Other: T-cell lymphocyte responses

First Posted Date: 2019-06-24

Last Posted Date: 2024-11-15

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 135

Registration Number: NCT03996018

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Inotuzumab ozogamicin
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Methylprednisolone

First Posted Date: 2019-04-12

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 32

Registration Number: NCT03913559

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Trial of Antibody Responses by Vitamin Supplementation

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Biological: No vitamin A supplementation
Biological: Vitamin A supplementation

First Posted Date: 2019-03-01

Last Posted Date: 2024-02-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 80

Registration Number: NCT03859687

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy